| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |